Publications

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2024)

A deep catalogue of protein-coding variation in 983,578 individuals.

Sun KY. et al, (2024), Nature

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Lifetime and 10-year risks of cardiovascular mortality in relation to risk factors in middle and old age: 50-year follow-up of the Whitehall study of London Civil Servants.

Clarke R. et al, (2024), Public Health, 230, 73 - 80

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.

Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40

Protein-truncating variants in BSN are associated with severe adult-onset 2 obesity, type 2 diabetes and fatty liver disease

EMBERSON J., (2024), Nature Genetics

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200

Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.

Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631

Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico City.

Ziyatdinov A. et al, (2024), Nature, 626

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group None., (2024), Diabetic medicine : a journal of the British Diabetic Association

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Independent relevance of adiposity measures to coronary heart disease risk among 0.5 million adults in UK Biobank.

Trichia E. et al, (2023), Int J Epidemiol, 52, 1836 - 1844

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses.

Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration None., (2023), Lancet Diabetes Endocrinol

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

A deep catalog of protein-coding variation in 985,830 individuals.

Sun KY. et al, (2023), bioRxiv

Cookies on this website

Publications